Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBoundless Bio, Inc. Common Stock

Boundless Bio, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.46 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
29953
Market Cap
35.85M

Momentum Score

…

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.43
Low
2.50
High
52 Week Price Range
0.96
Low
1.78
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Boundless Bio, Inc. (NASDAQ: BOLD) is a publicly listed clinical-stage biotechnology company focused on developing novel oncology therapies; its long-term growth may be driven by advancement of its clinical pipeline, successful regulatory approvals, and strategic collaborations that could provide development and commercialization support. Investors may find the company attractive because positive trial readouts or licensing deals can materially increase value for early-stage biotechs and open pathways to broader market opportunities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.46
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.50
ROE
-46.69%
Net Debt
31.17M
ROCE
-43.97%
Diluted EPS TTM
-2.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -58.20M -65.36M -49.43M -45.90M -25.21M
Net income -58.20M -65.36M -49.43M -45.90M -25.21M
Selling general administrative 18.71M 18.00M 12.16M 9.31M 6.02M
Gross profit -1.25M -1.09M -0.96M -0.94M -0.68M
Reconciled depreciation 1.25M 1.09M 0.96M 0.94M 0.68M
Ebit -63.55M -65.36M -54.80M -46.47M -25.30M
Ebitda -62.30M -64.28M -53.84M -45.53M -24.62M
Depreciation and amortization 1.25M 1.09M 0.96M 0.94M 0.68M
Operating income -63.55M -73.27M -54.80M -46.47M -25.30M
Other operating expenses 63.55M 73.27M 54.80M 46.47M 25.30M
Interest income 5.36M 7.89M 5.28M 0.67M 0.10M
Net interest income 5.36M 7.89M 5.28M 0.67M 0.10M
Income tax expense - -65.36M -5.28M -0.67M -0.10M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 62.30M 72.18M 54.80M 46.47M 25.30M
Cost of revenue 1.25M 1.09M 0.96M 0.94M 0.68M
Total other income expense net 5.36M 7.90M 0.08M -0.10M -0.01M
Net income from continuing ops -58.20M -65.36M -49.43M -45.90M -25.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 157.06M 206.41M 129.89M 76.83M 113.72M
Other current assets 2.03M 2.28M 3.45M 1.32M 1.54M
Total liab 58.41M 55.77M 256.98M 158.53M 151.91M
Total stockholder equity 98.65M 150.64M -127.08M -81.70M -38.19M
Other current liab 7.88M 6.86M 4.94M 0.09M 0.21M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -259.67M -201.47M -136.11M -86.67M -40.77M
Cash 17.87M 26.59M 23.71M 10.95M 34.29M
Total current liabilities 12.54M 8.13M 9.36M 7.73M 3.87M
Current deferred revenue - - - 3.90M 2.21M
Net debt 31.17M 21.05M -21.51M -5.77M -33.91M
Short term debt 3.17M - 2.19M 2.34M 0.38M
Short long term debt total 49.03M 47.63M 2.19M 5.18M 0.38M
Other stockholder equity 358.26M 351.99M 8.98M 5.38M 2.76M
Total current assets 109.61M 154.39M 124.20M 68.04M 74.57M
Long term investments - - - 0.00M 34.99M
Short term investments 89.71M 125.53M 97.05M 55.77M 38.74M
Accounts payable 1.49M 1.27M 2.22M 1.40M 1.07M
Accumulated other comprehensive income 0.06M 0.12M 0.04M -0.40M -0.17M
Non currrent assets other 0.57M 0.66M 0.56M 0.53M 1.07M
Non current assets total 47.45M 52.02M 5.69M 8.79M 39.15M
Capital lease obligations 49.03M 47.63M 2.19M 5.18M 0.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 38.35M -26.10M -38.26M 16.13M -59.28M
Total cashflows from investing activities 37.80M -26.10M - - -
Total cash from financing activities 0.14M 89.82M 97.90M 0.13M 105.53M
Net income -58.20M -65.36M -49.43M -45.90M -25.21M
Change in cash -8.72M 2.88M 12.78M -23.34M 22.99M
Begin period cash flow 27.15M 24.27M 11.48M 34.82M 11.83M
End period cash flow 18.43M 27.15M 24.27M 11.48M 34.82M
Total cash from operating activities -46.66M -60.84M -46.85M -39.60M -23.25M
Issuance of capital stock 0.00M 93.00M 99.67M 0.00M 105.32M
Depreciation 1.25M 1.09M 0.96M 0.94M 0.68M
Sale purchase of stock 0.14M 0.11M - - -
Other cashflows from financing activities 0.14M -3.18M 97.90M 16.13M -59.28M
Capital expenditures 0.55M 2.54M 0.63M 1.07M 2.03M
Change in working capital 3.46M -1.68M -0.80M 0.87M -0.84M
Stock based compensation 6.12M 7.52M 3.34M 2.29M 1.16M
Other non cash items 0.70M -2.40M 2.38M 1.70M 0.42M
Free cash flow -47.21M -63.38M -47.49M -40.66M -25.28M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
BOLD
Boundless Bio, Inc. Common Stock		 -
-%		 2.46 - - - 0.36
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Boundless Bio, Inc. Common Stock

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

10955 Alexandria Way, San Diego, CA, United States, 92121

858 766 9912

https://boundlessbio.com

28

Name Title Year Born
Dr. Jonathan E. Lim M.D. Co-Founder & Independent Chairman 1972
Mr. Zachary Hornby CEO, President & Director 1979
Dr. Christian Hassig Ph.D. Chief Scientific Officer 1973
Dr. Klaus W. Wagner M.D., Ph.D. Chief Medical Officer 1973
Ms. Jamilu E. Rubin Chief Financial Officer 1965
Ms. Jessica Oien J.D. Chief Legal Officer & Corporate Secretary 1972
Mr. Neil Abdollahian M.B.A., M.S. Chief Business Officer 1973
Mr. Anthony Pinkerton Ph.D. Senior Vice President of Drug Discovery NA
Ms. Meredith Wesley Senior Vice President of Talent & Culture NA
Dr. Shailaja Kasibhatla Ph.D. Senior Vice President of Discovery & Translational Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…